Tryptamine-based human β3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives
摘要:
A series of tryptamine derivatives with modified sulfonamide were designed, synthesized, and evaluated for their ability to stimulate CAMP accumulation in CHO cells expressing the cloned human beta(3)-adrenergic receptor (AR). For this series of compounds, our objective was to symmetrize the a-position of the tryptamine moiety maintaining its activity and reducing the cost of production. Compound 11h, having m-aminobenzene, exhibited excellent agonistic activity for beta(3)-AR with excellent subtype selectivity. (C) 2004 Elsevier Ltd. All rights reserved.
Tryptamine-based human β3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives
摘要:
A series of tryptamine derivatives with modified sulfonamide were designed, synthesized, and evaluated for their ability to stimulate CAMP accumulation in CHO cells expressing the cloned human beta(3)-adrenergic receptor (AR). For this series of compounds, our objective was to symmetrize the a-position of the tryptamine moiety maintaining its activity and reducing the cost of production. Compound 11h, having m-aminobenzene, exhibited excellent agonistic activity for beta(3)-AR with excellent subtype selectivity. (C) 2004 Elsevier Ltd. All rights reserved.
The continued SAR investigation of tryptamine-based human beta(3)-adrenergic receptor (AR) agonists is reported. Prior efforts resulted in the identification of 2 as a potent beta(3)-AR agonist. Further modification of the left side arylsulfonamide portion in 2 provided compounds with good cell permeability, which have potent agonistic activity for beta(3)-AR. Cinnamylamine analog 16i exhibited an excellent agonistic profile in vitro and good oral bioavailability in rats. (C) 2004 Elsevier Ltd. All rights reserved.